Clinical Evaluation of the XDR-LFC Assay for the Molecular Detection of Isoniazid, Rifampin, Fluoroquinolone, Kanamycin, Capreomycin, and Amikacin Drug Resistance in a Prospective Cohort
Journal of Clinical Microbiology · 2023
DOI: 10.1128/jcm.01478-22 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Microbiology, 2023. Verfasst von Rehan R Syed und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California, San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCATS NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
While the goal of universal drug susceptibility testing has been a key component of the WHO End TB Strategy, in practice, this remains inaccessible to many. Rapid molecular tests for tuberculosis (TB) and antituberculosis drug resistance could significantly improve access to testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of California, San Diego, La Jolla, California, USA.
- Department of Biological Sciences, University of Arkansas, Fayetteville, Arkansas, USA.
- Akonni Biosystems, Inc., Frederick, Maryland, USA.
- Phthisiopneumology Institute, Chișinău, Republic of Moldova.
- Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, California, USA.
ORCID-Profile: Rehan R Syed, Donald G Catanzaro, Rebecca E Colman, Marva Seifert
Förderung
- NIAID NIH HHS
- NCATS NIH HHS
- NIGMS NIH HHS
- NIBIB NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases
- HHS | NIH | National Institute of Biomedical Imaging and Bioengineering
- HHS | NIH | National Institute of General Medical Sciences
Zitieren
APA
Syed, R. R., Catanzaro, D. G., Colman, R. E., Cooney, C. G., Linger, Y., Kukhtin, A. V., Holmberg, R. C., Norville, R., Crudu, V., Ciobanu, N., Codreanu, A., Seifert, M., Hillery, N., Chiles, P., Catanzaro, A., & Rodwell, T. C. (2023). Clinical Evaluation of the XDR-LFC Assay for the Molecular Detection of Isoniazid, Rifampin, Fluoroquinolone, Kanamycin, Capreomycin, and Amikacin Drug Resistance in a Prospective Cohort. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.01478-22
Vancouver
Syed RR, Catanzaro DG, Colman RE, Cooney CG, Linger Y, Kukhtin AV, et al. Clinical Evaluation of the XDR-LFC Assay for the Molecular Detection of Isoniazid, Rifampin, Fluoroquinolone, Kanamycin, Capreomycin, and Amikacin Drug Resistance in a Prospective Cohort. Journal of Clinical Microbiology. 2023. doi:10.1128/jcm.01478-22
BibTeX
@article{Syed2023,
author = {Syed, Rehan R and Catanzaro, Donald G and Colman, Rebecca E and Cooney, Christopher G and Linger, Yvonne and Kukhtin, Alexander V and Holmberg, Rebecca C and Norville, Ryan and Crudu, Valeriu and Ciobanu, Nelly and Codreanu, Alexandru and Seifert, Marva and Hillery, Naomi and Chiles, Peter and Catanzaro, Antonino and Rodwell, Timothy C},
title = {Clinical Evaluation of the XDR-LFC Assay for the Molecular Detection of Isoniazid, Rifampin, Fluoroquinolone, Kanamycin, Capreomycin, and Amikacin Drug Resistance in a Prospective Cohort},
journal = {Journal of Clinical Microbiology},
year = {2023},
doi = {10.1128/jcm.01478-22}
}
EUVIMED